CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- ----------------------
2003 2002 2003 2002
-------- -------- -------- --------
Revenues:
Product Sales $ 897 $ 493 $ 2,430 $ 2,861
Operating expenses:
Product Costs 1,750 1,542 4,714 4,569
Research and development costs 304 219 953 640
Selling, general and administrative costs (non-cash of $ 1,165 and $ 6,354
for the three months and nine months ended September 30, 2003, respectively
and non-cash of $ 79 and $616 for the three months and nine months ended
September 30, 2002, respectively) 2,754 1,565 12,371 4,867
Total operating expenses 4,808 3,326 18,038 10,076
Loss from operations (3,911) (2,833) (15,608) (7,215)
Interest income (expense) (non-cash of ($ 3,168) and ($ 5,655)
for the three months and nine months ended September 30,
2003, respectively and non-cash of $ 1,475 and ($ 997) for
the three months and nine months ended September 30, 2002, (3,282) 1,326 (6,054) (1,210)
respectively)
Gain on settlement of trade debt -- -- -- 1,319
Other income (expense), net (30) 12 174 33
-------- -------- -------- --------
Loss before income taxes (7,223) (1,495) (21,488) (7,073)
Income taxes -- -- (2) (2)
-------- -------- -------- --------
Net loss (7,223) (1,495) (21,490) (7,075)
Less dividends on mandatorily redeemable Series A preferred stock (30) (30) (90) (90)
-------- -------- -------- --------
Net loss attributable to common stockholders $ (7,253) $ (1,525) $(21,580) $ (7,165)
======== ======== ======== ========
Net loss per share attributable to common stockholders (basic
and diluted) $ (0.11) $ (0.51) $ (0.75) $ (3.41)
======== ======== ======== ========
Weighted average shares used to compute net loss per share
attributable to common stockholders (basic and diluted) 68,862 2,976 28,796 2,098
======== ======== ======== ========
See accompanying notes to consolidated financial statements. |
